X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
A phase 1 trial of Mavorixafor and Pembrolizumab in Melanoma, run by X4 Pharmaceuticals, completed.
Overview
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma is a phase 1 interventional study registered as NCT02823405 by X4 Pharmaceuticals, with 16 participants recorded, started 2016-09-15 and reaching its primary completion in 2018-03-15. Interventions recorded: X4P-001, Pembrolizumab. Conditions recorded: Melanoma.
Linked to the drug Mavorixafor because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Shares X4 Pharmaceuticals, Mavorixafor and the tag pipeline.
- TrialPembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Shares Melanoma, Pembrolizumab and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Melanoma, Pembrolizumab and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab and the tag pipeline.
- TrialIsunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Shares Pembrolizumab and the tag pipeline.
- TrialN-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Shares Pembrolizumab and the tag pipeline.